IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO
May 08, 2024 08:00 ET
|
Imunon, Inc.
Assumes leadership role as Company anticipates multiple near-term clinical milestones Brings extensive leadership and experience in drug development and business strategy LAWRENCEVILLE, N.J.,...
Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
May 08, 2024 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and...
SRAX Signs Agreement to Merge with DNA Holdings
May 08, 2024 08:00 ET
|
SRAX, Inc.
Westlake Village, CA, May 08, 2024 (GLOBE NEWSWIRE) -- SRAX Inc. (OTC: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through its SaaS platform...
Aspira Women’s Health to Announce First Quarter Earnings Results and Host a Conference Call on Wednesday, May 15
May 08, 2024 08:00 ET
|
Aspira Women's Health Inc.
AUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of...
Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights
May 08, 2024 08:00 ET
|
Clene Inc.
Data from long-term extension of Phase 2 VISIONARY-MS clinical trial of CNM-Au8® demonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints (change from...
Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
May 08, 2024 08:00 ET
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., May 08, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic...
60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases
May 08, 2024 07:59 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma plans clinical trial of Tafenoquine for Babesiosis. Letter to Journal of Infectious Diseases outlines protocol. Enrollment starts summer.
Vericel Reports First Quarter 2024 Financial Results and Raises Full-Year 2024 Financial Guidance
May 08, 2024 07:55 ET
|
Vericel Corporation
Total Revenue Increased 25% to $51.3 Million Record First Quarter MACI Revenue of $40.2 Million and Burn Care Revenue Growth of 63% Adjusted EBITDA Growth of 325% Full-Year 2024 Revenue Guidance...
Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference
May 08, 2024 07:40 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of...
MasterCraft Boat Holdings, Inc. Reports Results for Fiscal 2024 Third Quarter
May 08, 2024 07:30 ET
|
MasterCraft Boat Holdings, Inc.
VONORE, Tenn., May 08, 2024 (GLOBE NEWSWIRE) -- MasterCraft Boat Holdings, Inc. (NASDAQ: MCFT) today announced financial results for its fiscal 2024 third quarter ended March 31, 2024. The...